A new article published in Allergy discussed that food allergies have become a significant heath burden, as its prevalence continues to rise, affecting 6-13% of the global population. In the absence of approved drugs, the current standard of care remains the avoidance of allergenic foods and management of acute allergic reactions with antihistamines and epinephrine auto-injectors. The authors reported that allergen immunotherapy has shown to increase the threshold of reactivity in a majority of food-allergic individuals. Challenges include long treatment periods, high rates of adverse reaction sand lack of permanence of desensitization and established protocols. To address these limitations, adjunctive allergen-specific immunotherapy, vaccines and non-allergen specific the rapies like monoclonal antibodies, are being explored. This article inferred that the future of food allergy treatment is promising, with a number of clinical trials in progress. Currently, although desensitization can be achieved for a majority of individuals with food allergy through immunotherapy, continued ingestion of allergen is required for most individuals to maintain desensitization.